Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.

Romilkimab delivers in diffuse cutaneous systemic sclerosis

6 days ago

Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis (dcSSc), producing significant reduction in skin fibrosis, according to data from a phase II trial.

Ninety-seven adult dcSSc patients with or without immunosuppressive background therapy were randomized to receive either romilkimab (n=48) or placebo (n=49) for 24 weeks.

The primary endpoint of change in modified Rodnan skin score (mRSS) at week 24 was significantly greater with the study drug than with placebo (–4.76 vs –2.45; difference, –2.31, 95 percent confidence interval, –4.32 to –0.31; p=0.0291).

There were no significant differences observed in the secondary endpoints of forced vital capacity (–10 mL with romilkimab vs –80 mL with placebo; p=0.10), diffusing lung capacity for carbon monoxide (–0.12 vs –0.27, respectively; p=0.14), and physical/functional disability (mean Health Assessment Questionnaire-Disability Index score, –0.09 vs –0.12, respectively; p=0.40).

Treatment-emergent adverse event were comparable between romilkimab and placebo (80 percent vs 84 percent), with most events being mild to moderate in severity and rarely leading to discontinuations (three overall).

There were two deaths documented, one due to scleroderma renal crisis in the active treatment group and the other due to cardiomyopathy in the placebo group, but neither was considered treatment related. There were no cardiac safety signals detected with romilkimab.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.